Vendor Neutral Archive (VNA) & PACS Market - Global Forecast To 2030
商品番号 : SMB-56866
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 289 |
| 図表数 | 371 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、ベンダーニュートラルアーカイブ（VNA）およびPACS市場を分析し、製品タイプ、モダリティ、導入環境、ベンダータイプ、用途、エンドユーザー、地域に基づいて、様々な市場セグメントの市場規模と将来の成長可能性を予測しています。また、この市場における主要プレーヤーの競合分析に加え、各社の企業概要、製品ラインナップ、最近の動向、主要な市場戦略も提供しています。
The global VNA & PACS market is projected to reach USD 7.92 billion by 2030 from USD 5.10 billion in 2025, at a CAGR of 9.2% during the forecast period. Market expansion is largely fueled by the surging volume of medical imaging data, the transition towards enterprise-wide interoperability, and the increasing demand for centralized, vendor-neutral platforms designed to optimize imaging workflows. Additionally, initiatives aimed at healthcare digitization and regulatory frameworks promoting health information exchange are further catalyzing market growth. However, the high costs associated with implementation and the complexities related to data migration remain significant barriers to the adoption of advanced VNA and PACS, particularly for small to mid-sized healthcare organizations.
世界のVNAおよびPACS市場は、2025年の51億米ドルから2030年には79億2000万米ドルに達し、予測期間中に9.2%の年平均成長率（CAGR）で成長すると予測されています。市場拡大の大きな原動力となっているのは、医療画像データの急増、企業全体にわたる相互運用性への移行、そして画像処理ワークフローを最適化するために設計された集中型のベンダー中立型プラットフォームへの需要の高まりです。さらに、医療のデジタル化に向けた取り組みや、医療情報交換を促進する規制の枠組みも、市場の成長をさらに促進しています。しかしながら、導入に伴う高額なコストとデータ移行の複雑さは、特に中小規模の医療機関にとって、高度なVNAおよびPACSの導入における大きな障壁となっています。
On the basis of product type, the multi-site VNA segment is expected to witness the highest growth rate during the forecast period.
Based on product type, the VNA & PACS market is segmented into VNA (further subsegmented into department, multi-department, and multi-site VNA) and PACS (further subsegmented into department, multi-department, and multi-site PACS). The multi-site VNA subsegment is expected to witness the fastest CAGR during the forecast period. The escalating demand for medical imaging solutions is primarily driven by the increasing emphasis of healthcare systems on interoperability and cross-institutional data integration to optimize imaging workflows across diverse geographical locations. As hospitals and health systems consolidate into integrated networks, the establishment of a comprehensive imaging repository has become essential for facilitating seamless data access and collaborative diagnostic efforts. Additionally, the transition towards remote diagnostics, teleconsultations, and virtual care frameworks—exacerbated by the COVID-19 pandemic—has underscored the imperative for scalable, multi-site VNAs that enable secure and anytime-anywhere access to medical imaging. These advanced solutions not only help dismantle data silos and minimize image duplication but also enhance care coordination across various departments and facilities.
On the basis of deployment, the on-premises deployment segment held the largest market share in 2024.
On the basis of deployment, the VNA & PACS market has been segmented into on-premises, cloud-based, and hybrid deployment. The on-premises deployment segment held the largest market share in 2024. Healthcare institutions are increasingly favoring on-premises deployment in infrastructure to maintain oversight and achieve long-term cost predictability, particularly those with substantial resources or large-scale operations. These organizations prioritize security and performance stability, which aligns well with capital budgeting practices. By managing storage internally, they ensure compliance with stringent data governance standards while consistently delivering reliable imaging performance. A critical consideration in this area is the total cost of ownership (TCO). Although cloud-based solutions typically offer greater agility and require a lower upfront investment, on-premises deployment often provides superior long-term return on investment (ROI), especially for institutions equipped with established IT teams and fixed imaging volume requirements. Furthermore, advancements in hardware efficiencies are making local deployments increasingly economical and dependable.
On the basis of region, the Asia Pacific is expected to witness the highest CAGR from 2025 to 2030.
On the basis of region, the VNA & PACS market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Among these, the Asia Pacific market is expected to witness the highest CAGR due to an increased investment in medical imaging infrastructure, expanding healthcare access, and the rapid digitization of hospital systems across emerging economies. Countries such as India, China, and various Southeast Asian nations are enhancing their diagnostic imaging capabilities, leading healthcare organizations to explore centralized and interoperable solutions for the management of clinical images and associated data. Concurrently, technological advancements and the increasing adoption of cloud computing are rendering enterprise imaging solutions—specifically VNA and PACS—more scalable and cost-efficient across institutions of varying sizes. As digital health strategies emerge as national imperatives, there is an intensified focus on optimizing imaging workflows, facilitating remote access to radiological data, and promoting cross-facility data interoperability. These objectives are well-aligned with the inherent advantages offered by VNA and PACS platforms, which support integrated and seamless management of imaging information.
The breakdown of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
- By Region – North America: 32%, Europe: 30%, Asia Pacific: 25%, Middle East & Africa: 5%, Latin America: 5%
Key Players
The key players functioning in the VNA & PACS market include Hyland Software, Inc. (US), Agfa-Gevaert Group (Belgium), Intelerad Medical Systems Inc. (Canada), Canon Medical Systems Corporation (Japan), FUJIFILM Holdings Corporation (Japan), GE Healthcare (US), Merative (US), Sectra AB (Sweden), Siemens Healthcare Limited (Germany), BridgeHead Software Ltd. (UK), Canopy Partners. (US), Novarad Corporation (US), POSTDICOM (Netherlands), AdvaHealth Solutions Pte Ltd. (Singapore), CrelioHealth (India), Medicasoft (US), Esaote S.p.A. (Italy), PaxeraHealth (US), VISUS Health IT GmbH (Germany), ASPYRA, LLC (US), Dedalus S.p.A. (Italy), SoftTeam Solutions Pvt. Ltd. (India), ARO Systems (Australia), Central Data Networks (Australia), and ONEPACS (US).
Research Coverage:
The report analyses the VNA & PACS market to estimate the market size and future growth potential of various market segments based on product type, modality, deployment, vendor type, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report provides valuable insights for both established firms and emerging or smaller players, enabling them to accurately assess market dynamics. By leveraging the information presented, organizations can adopt various strategies outlined below to enhance their competitive positioning and increase market share..
This report provides insights on:
Analysis of DROCs: Drivers [increasing investments in medical imaging technologies, growing demand for streamlined healthcare data management solutions, Integration of PACS/VNA with electronic medical records (EMRs)], restraints [increasing data security and privacy concerns, high initial investment, lack of standardized protocols and interoperability frameworks], opportunities [government initiatives to increase penetration of Al in medical imaging, Increasing medical imaging procedures and large imaging data silos, rapid uptake of big data in healthcare], and challenges [rising security concerns related to cloud-based image processing and analytics, data security issues] influencing the growth of the VNA & PACS market.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product & service launches in the VNA & PACS market
- Market Development: Comprehensive information on the lucrative emerging markets, product type, modality, deployment, vendor type, application, end user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the VNA & PACS market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the VNA & PACS market, such as Agfa-Gevaert Group (Belgium), FUJIFILM Holdings Corporation (Japan), Sectra AB (Sweden), Merative (US), and GE Healthcare (US).
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 28
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 28
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.1.1 SECONDARY DATA 32
2.1.1.1 Key secondary sources 33
2.1.1.2 Key data from secondary sources 33
2.1.2 PRIMARY DATA 34
2.1.2.1 Key primary sources 34
2.1.2.2 Key objectives of primary research 34
2.1.2.3 Key data from primary sources 35
2.1.2.4 Key primary insights 36
2.2 RESEARCH DESIGN 37
2.3 MARKET SIZE ESTIMATION 38
2.3.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 38
2.3.2 BOTTOM-UP APPROACH 40
2.3.3 TOP-DOWN APPROACH 40
2.3.4 TOP-DOWN APPROACH FOR PARENT MARKET ASSESSMENT 41
2.3.5 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 41
2.4 DATA TRIANGULATION 45
2.5 STUDY ASSUMPTIONS 46
2.6 RISK ANALYSIS 47
2.7 RESEARCH LIMITATIONS 47
2.7.1 METHODOLOGY-RELATED LIMITATIONS 47
2.7.2 SCOPE-RELATED LIMITATIONS 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 53
4.1 OVERVIEW OF VNA & PACS MARKET 53
4.2 ASIA PACIFIC: VNA & PACS MARKET, BY PRODUCT TYPE AND COUNTRY 54
4.3 VNA & PACS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
4.4 VNA & PACS MARKET: REGIONAL MIX 56
4.5 VNA & PACS MARKET: DEVELOPED VS. EMERGING MARKETS 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 57
5.2.1.1 Heightened investments in medical imaging technologies 57
5.2.1.2 Growing demand for streamlined healthcare data management solutions 58
5.2.1.3 Integration of PACS/VNA with electronic medical records 58
5.2.2 RESTRAINTS 59
5.2.2.1 High initial investment for implementing VNA and PACS solutions 59
5.2.2.2 Lack of standardized protocols and interoperability frameworks 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Favorable government initiatives for better penetration of Al in medical imaging 60
5.2.3.2 Increasing medical imaging procedures and large imaging data silos 60
5.2.3.3 Rapid uptake of big data in healthcare 60
5.2.4 CHALLENGES 61
5.2.4.1 Rising security concerns related to cloud-based image processing and analytics 61
5.2.4.2 Data security issues in healthcare settings 62
5.3 INDUSTRY TRENDS 62
5.3.1 CLOUD ADOPTION 62
5.3.2 AI AND ML INTEGRATION 62
5.3.3 VALUE-BASED CARE MODELS 63
5.4 TECHNOLOGY ANALYSIS 63
5.4.1 KEY TECHNOLOGIES 63
5.4.1.1 Digital imaging and communications in medicine (DICOM) 63
5.4.1.2 Enterprise imaging solutions 63
5.4.1.3 Cloud-based storage and services 63
5.4.2 COMPLEMENTARY TECHNOLOGIES 63
5.4.2.1 Image exchange networks 63
5.4.2.2 Data analytics and business intelligence 63
5.4.3 ADJACENT TECHNOLOGIES 64
5.4.3.1 Health information exchange (HIE) 64
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 64
5.6 VALUE CHAIN ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 66
5.7.1 ROLE IN ECOSYSTEM 68
5.8 INVESTMENT & FUNDING SCENARIO 69
5.9 PORTER’S FIVE FORCES ANALYSIS 69
5.9.1 INTENSITY OF COMPETITIVE RIVALRY 71
5.9.2 BARGAINING POWER OF SUPPLIERS 71
5.9.3 BARGAINING POWER OF BUYERS 71
5.9.4 THREAT OF NEW ENTRANTS 71
5.9.5 THREAT OF SUBSTITUTES 71
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 72
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
5.10.2 KEY BUYING CRITERIA 72
5.11 KEY CONFERENCES & EVENTS, 2025–2026 73
5.12 PRICING ANALYSIS 74
5.12.1 AVERAGE SELLING PRICE OF VNA & PACS SOLUTIONS, BY PRODUCT TYPE, 2024 74
5.12.2 AVERAGE SELLING PRICE OF VNA & PACS SOLUTIONS, BY REGION (QUALITATIVE) 75
5.13 REGULATORY ANALYSIS 76
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
5.13.2 REGULATORY FRAMEWORK 78
5.13.2.1 North America 78
5.13.2.1.1 US 78
5.13.2.2 Europe 78
5.13.2.3 Asia Pacific 78
5.13.2.3.1 China 78
5.13.2.3.2 Japan 78
5.13.2.3.3 India 79
5.14 PATENT ANALYSIS 79
5.14.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 79
5.14.2 LIST OF MAJOR PATENTS, 2020–2024 81
5.15 CASE STUDY ANALYSIS 81
5.15.1 AMBRA HEALTH UTILIZED AWS CLOUD SERVICES TO PROPEL MEDICAL IMAGING PLATFORM GROWTH 81
5.15.2 NHS TRUST ADOPTED INSTANT DATA ACCESS VNA TO ESTABLISH UNIFIED PLATFORM FOR DICOM IMAGE DATA STORAGE AND MANAGEMENT 82
5.16 UNMET NEEDS & END-USER EXPECTATIONS 82
5.16.1 UNMET NEEDS 82
5.16.2 END-USER EXPECTATIONS 84
5.17 BUSINESS MODELS 84
5.17.1 ENTERPRISE LICENSING MODELS 84
5.17.2 SOFTWARE-AS-A-SERVICE (SAAS) MODELS 84
5.17.3 PAY-PER-USE MODELS 84
5.17.4 HYBRID MODELS 84
5.18 IMPACT OF 2025 US TARIFF ON VNA & PACS MARKET 85
5.18.1 INTRODUCTION 85
5.18.2 KEY TARIFF RATES 85
5.18.3 PRICE IMPACT ANALYSIS 85
5.18.4 IMPACT ON COUNTRY/REGION 86
5.18.4.1 North America 86
5.18.4.1.1 US 86
5.18.4.2 Europe 86
5.18.4.3 Asia Pacific 86
5.18.5 IMPACT ON END-USE INDUSTRIES 87
5.18.5.1 Hospitals & clinics 87
5.18.5.2 Diagnostics centers 87
5.18.5.3 Ambulatory surgery centers 87
5.18.5.4 Other end users 87
5.18.6 CONCLUSION 87
6 VNA & PACS MARKET, BY MODALITY 88
6.1 INTRODUCTION 89
6.2 CT 89
6.2.1 GROWING NEED FOR IMAGING MODALITIES IN MEDICAL FIELDS TO SUPPORT MARKET GROWTH 89
6.3 MAMMOGRAPHY 90
6.3.1 RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET GROWTH 90
6.4 ULTRASOUND 91
6.4.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND DEVICES TO AID MARKET GROWTH 91
6.5 MRI 92
6.5.1 COST-EFFECTIVENESS AND EASY AVAILABILITY IN SMALL HEALTHCARE FACILITIES TO FUEL MARKET ADOPTION 92
6.6 X-RAY 94
6.6.1 DEVELOPMENTS IN X-RAY IMAGING TO BOOST ADOPTION OF VNA AND PACS SOLUTIONS 94
6.7 PET 95
6.7.1 NEED FOR BETTER MANAGEMENT AND STORAGE OF LARGE DATA VOLUMES TO FAVOR MARKET GROWTH 95
7 VNA & PACS MARKET, BY DEPLOYMENT MODEL 97
7.1 INTRODUCTION 98
7.2 ON-PREMISES DEPLOYMENT MODELS 98
7.2.1 BETTER CONTROL AND SECURITY FOR SENSITIVE PATIENT DATA TO AUGMENT MARKET GROWTH 98
7.3 CLOUD-BASED DEPLOYMENT MODELS 99
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET 99
7.4 HYBRID DEPLOYMENT MODELS 101
7.4.1 GREATER FLEXIBILITY, SCALABILITY, AND CONTROL OVER DATA MANAGEMENT STRATEGIES TO PROPEL MARKET GROWTH 101
8 VNA & PACS MARKET, BY PRODUCT TYPE 103
8.1 INTRODUCTION 104
8.2 VNA 104
8.2.1 DEPARTMENT VNA 106
8.2.1.1 Limitations in addressing scalability and interoperability across diverse departments to hinder market growth 106
8.2.2 MULTI-DEPARTMENT VNA 106
8.2.2.1 Multi-department VNA to streamline data management processes and reduce redundancies 106
8.2.3 MULTI-SITE VNA 107
8.2.3.1 Multi-site VNA to provide centralized repository for managing medical data and standardizing medical records 107
8.3 PACS 108
8.3.1 DEPARTMENT PACS 110
8.3.1.1 Need for better medical imaging data storage to aid market growth 110
8.3.2 MULTI-DEPARTMENT PACS 110
8.3.2.1 Technological advancements in multi-department PACS to improve image retrieval speed and ensure data integrity 110
8.3.3 MULTI-SITE PACS 111
8.3.3.1 Advancements in cloud-based PACS solutions to propel market growth 111
9 VNA & PACS MARKET, BY VENDOR TYPE 113
9.1 INTRODUCTION 114
9.2 INDEPENDENT VENDORS 114
9.2.1 INCREASED FLEXIBILITY, BETTER INTEROPERABILITY, AND IMPROVED SOLUTIONS TO DRIVE MARKET 114
9.3 THIRD-PARTY VENDORS 116
9.3.1 NEED FOR INNOVATIVE SOLUTIONS TO DRIVE THIRD-PARTY VENDOR PRESENCE 116
10 VNA & PACS MARKET, BY APPLICATION 118
10.1 INTRODUCTION 119
10.2 CARDIOLOGY 119
10.2.1 RISING CASES OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 119
10.3 ORTHOPEDIC 120
10.3.1 GROWING VOLUME AND COMPLEXITY OF ORTHOPEDIC MEDICAL IMAGING SCANS TO PROPEL MARKET GROWTH 120
10.4 ONCOLOGY 121
10.4.1 RISING NUMBER OF CANCER CASES TO DRIVE USE OF VNA AND PACS SOLUTIONS FOR ONCOLOGY 121
10.5 NEUROLOGY 122
10.5.1 INCREASING DEMAND FOR ADVANCED NEUROLOGICAL IMAGING TECHNOLOGIES TO SPUR GROWTH 122
10.6 OBSTETRICS & GYNECOLOGY 123
10.6.1 USE OF 3D AND 4D IMAGING FOR MONITORING FETUS GROWTH AND DIAGNOSING HIGH-RISK PREGNANCIES TO DRIVE MARKET 123
10.7 OTHER APPLICATIONS 124
11 VNA & PACS MARKET, BY END USER 126
11.1 INTRODUCTION 127
11.2 HOSPITALS & CLINICS 127
11.2.1 NEED TO IMPROVE PROFITABILITY OF HEALTHCARE SERVICES TO DRIVE USE OF HCIT IN HOSPITALS 127
11.3 DIAGNOSTIC CENTERS 128
11.3.1 LACK OF ADVANCED IMAGING MODALITIES IN SMALL AND MID-SCALE HOSPITALS TO AUGMENT MARKET GROWTH 128
11.4 AMBULATORY SURGERY CENTERS 129
11.4.1 INCREASING NUMBER OF INTERVENTIONAL IMAGING PROCEDURES TO SUPPORT MARKET GROWTH 129
11.5 OTHER END USERS 130
12 VNA & PACS MARKET, BY REGION 132
12.1 INTRODUCTION 133
12.2 NORTH AMERICA 134
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 138
12.2.2 US 138
12.2.2.1 US to dominate global VNA & PACS market during study period 138
12.2.3 CANADA 142
12.2.3.1 Rising cases of end-stage kidney diseases to propel market growth 142
12.3 EUROPE 145
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 146
12.3.2 GERMANY 150
12.3.2.1 Increasing number of MRI units and diagnostic imaging centers to drive market 150
12.3.3 UK 153
12.3.3.1 Rising funding and investments in diagnostic imaging to support market growth 153
12.3.4 FRANCE 157
12.3.4.1 Rising target patient population and increasing government-funded investments to fuel uptake of VNA and PACS solutions 157
12.3.5 ITALY 160
12.3.5.1 Established healthcare infrastructure to aid market growth 160
12.3.6 SPAIN 163
12.3.6.1 Growing access to advanced cancer diagnostics to propel market 163
12.3.7 REST OF EUROPE 166
12.4 ASIA PACIFIC 169
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 170
12.4.2 JAPAN 174
12.4.2.1 Presence of universal healthcare coverage to fuel market 174
12.4.3 CHINA 177
12.4.3.1 Strong government support for healthcare reforms and increased number of medical imaging procedures to drive market 177
12.4.4 INDIA 180
12.4.4.1 Improving healthcare infrastructure and increasing private-public partnerships to support market growth 180
12.4.5 REST OF ASIA PACIFIC 183
12.5 LATIN AMERICA 186
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 186
12.5.2 BRAZIL 190
12.5.2.1 Presence of free and universal healthcare system to propel market growth 190
12.5.3 MEXICO 193
12.5.3.1 Rapid technological advancements in imaging solutions to support market growth 193
12.5.4 REST OF LATIN AMERICA 196
12.6 MIDDLE EAST & AFRICA 199
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 199
12.6.2 GCC COUNTRIES 203
12.6.2.1 Technological integration to spur inclusivity, accessibility, affordability, and growth in healthcare sector 203
12.6.3 REST OF MIDDLE EAST & AFRICA 206
13 COMPETITIVE LANDSCAPE 211
13.1 INTRODUCTION 211
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 211
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VNA & PACS MARKET 211
13.3 REVENUE ANALYSIS, 2020–2024 213
13.4 MARKET SHARE ANALYSIS, 2024 214
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 217
13.5.1 STARS 217
13.5.2 EMERGING LEADERS 217
13.5.3 PERVASIVE PLAYERS 217
13.5.4 PARTICIPANTS 217
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 219
13.5.5.1 Company footprint 219
13.5.5.2 Region footprint 220
13.5.5.3 Product type footprint 221
13.5.5.4 Deployment model footprint 222
13.5.5.5 End-user footprint 223
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 224
13.6.1 PROGRESSIVE COMPANIES 224
13.6.2 RESPONSIVE COMPANIES 224
13.6.3 DYNAMIC COMPANIES 224
13.6.4 STARTING BLOCKS 224
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 226
13.6.5.1 Detailed list of key startups/SME players 226
13.6.5.2 Competitive benchmarking of startups/SME players 227
13.7 COMPANY VALUATION & FINANCIAL METRICS 228
13.7.1 FINANCIAL METRICS 228
13.7.2 COMPANY VALUATION 228
13.8 BRAND/SOFTWARE COMPARISON 229
13.9 COMPETITIVE SCENARIO 230
13.9.1 PRODUCT LAUNCHES 230
13.9.2 DEALS 230
13.9.3 OTHER DEVELOPMENTS 231
14 COMPANY PROFILES 232
14.1 KEY COMPANIES 232
14.1.1 AGFA-GEVAERT GROUP 232
14.1.1.1 Business overview 232
14.1.1.2 Solutions offered 234
14.1.1.3 Recent developments 234
14.1.1.3.1 Deals 234
14.1.1.4 MnM view 235
14.1.1.4.1 Right to win 235
14.1.1.4.2 Strategic choices 235
14.1.1.4.3 Weaknesses & competitive threats 235
14.1.2 FUJIFILM HOLDINGS CORPORATION 236
14.1.2.1 Business overview 236
14.1.2.2 Solutions offered 237
14.1.2.3 Recent developments 239
14.1.2.3.1 Deals 239
14.1.2.3.2 Other developments 239
14.1.2.4 MnM view 239
14.1.2.4.1 Right to win 239
14.1.2.4.2 Strategic choices 239
14.1.2.4.3 Weaknesses & competitive threats 240
14.1.3 SECTRA AB 241
14.1.3.1 Business overview 241
14.1.3.2 Solutions offered 242
14.1.3.3 MnM view 243
14.1.3.3.1 Right to win 243
14.1.3.3.2 Strategic choices 243
14.1.3.3.3 Weaknesses & competitive threats 243
14.1.4 GE HEALTHCARE 244
14.1.4.1 Business overview 244
14.1.4.2 Solutions offered 245
14.1.4.3 Recent developments 246
14.1.4.3.1 Product launches 246
14.1.4.3.2 Deals 246
14.1.4.4 MnM view 246
14.1.4.4.1 Right to win 246
14.1.4.4.2 Strategic choices 246
14.1.4.4.3 Weaknesses & competitive threats 247
14.1.5 MERATIVE 248
14.1.5.1 Business overview 248
14.1.5.2 Solutions offered 248
14.1.5.3 Recent developments 249
14.1.5.3.1 Deals 249
14.1.5.4 MnM view 249
14.1.5.4.1 Right to win 249
14.1.5.4.2 Strategic choices 249
14.1.5.4.3 Weaknesses & competitive threats 249
14.1.6 KONINKLIJKE PHILIPS N.V. 250
14.1.6.1 Business overview 250
14.1.6.2 Solutions offered 251
14.1.6.3 Recent developments 252
14.1.6.3.1 Product launches 252
14.1.6.3.2 Deals 252
14.1.7 CANON MEDICAL SYSTEMS CORPORATION 253
14.1.7.1 Business overview 253
14.1.7.2 Solutions offered 254
14.1.7.3 Recent developments 255
14.1.7.3.1 Deals 255
14.1.7.3.2 Expansions 255
14.1.8 INTELERAD. INTELERAD. 256
14.1.8.1 Business overview 256
14.1.8.2 Solutions offered 256
14.1.8.3 Recent developments 257
14.1.8.3.1 Deals 257
14.1.8.3.2 Other developments 257
14.1.9 PAXERAHEALTH 258
14.1.9.1 Business overview 258
14.1.9.2 Solutions offered 258
14.1.10 NOVARAD CORPORATION 259
14.1.10.1 Business overview 259
14.1.10.2 Solutions offered 259
14.1.11 HYLAND SOFTWARE, INC. 260
14.1.11.1 Business overview 260
14.1.11.2 Solutions offered 260
14.1.11.3 Recent developments 261
14.1.11.3.1 Deals 261
14.1.12 SIEMENS HEALTHINEERS AG 262
14.1.12.1 Business overview 262
14.1.12.2 Solutions offered 263
14.1.12.3 Recent developments 264
14.1.12.3.1 Deals 264
14.1.13 BRIDGEHEAD SOFTWARE LTD. 265
14.1.13.1 Business overview 265
14.1.13.2 Solutions offered 265
14.1.13.3 Recent developments 266
14.1.13.3.1 Deals 266
14.1.14 CANOPY PARTNERS 267
14.1.14.1 Business overview 267
14.1.14.2 Solutions offered 267
14.1.15 CRELIOHEALTH INC. 268
14.1.15.1 Business overview 268
14.1.15.2 Solutions offered 268
14.1.16 ASPYRA, LLC 269
14.1.16.1 Business overview 269
14.1.16.2 Solutions offered 269
14.1.17 POSTDICOM 270
14.1.17.1 Business overview 270
14.1.17.2 Solutions offered 270
14.1.18 MEDICASOFT 271
14.1.18.1 Business overview 271
14.1.18.2 Solutions offered 271
14.1.19 ESAOTE S.P.A. 272
14.1.19.1 Business overview 272
14.1.19.2 Solutions offered 272
14.1.19.3 Recent developments 273
14.1.19.3.1 Product launches 273
14.1.20 VISUS HEALTH IT GMBH 274
14.1.20.1 Business overview 274
14.1.20.2 Solutions offered 274
14.2 OTHER PLAYERS 275
14.2.1 ADVAHEALTH SOLUTIONS 275
14.2.2 SOFTTEAM SOLUTIONS PVT. LTD. 276
14.2.3 ARO SYSTEMS 276
14.2.4 CENTRAL DATA NETWORKS 277
14.2.5 ONEPACS 277
14.2.6 DEDALUS S.P.A. 278
15 APPENDIX 279
15.1 DISCUSSION GUIDE 279
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 285
15.3 CUSTOMIZATION OPTIONS 287
15.4 RELATED REPORTS 287
15.5 AUTHOR DETAILS 288
LIST OF TABLES
TABLE 1 VNA & PACS MARKET: INCLUSIONS & EXCLUSIONS 29
TABLE 2 VNA & PACS MARKET: FACTOR ANALYSIS 42
TABLE 3 VNA & PACS MARKET: STUDY ASSUMPTIONS 46
TABLE 4 VNA & PACS MARKET: RISK ANALYSIS 47
TABLE 5 VNA & PACS MARKET: ROLE IN ECOSYSTEM 68
TABLE 6 VNA & PACS MARKET: PORTER’S FIVE FORCES 70
TABLE 7 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FOR MAJOR END USERS 72
TABLE 8 KEY BUYING CRITERIA FOR MAJOR END USERS 73
TABLE 9 VNA & PACS MARKET: LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025–DECEMBER 2026 73
TABLE 10 AVERAGE SELLING PRICE OF PACS SOLUTIONS, BY PRODUCT TYPE, 2024 75
TABLE 11 AVERAGE SELLING PRICE OF VNA SOLUTIONS, BY PRODUCT TYPE, 2024 75
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 16 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR VNA & PACS SOLUTIONS 79
TABLE 17 VNA & PACS MARKET: LIST OF PATENTS/PATENT APPLICATIONS,
2020–2024 81
TABLE 18 CASE STUDY 1: AMBRA HEALTH UTILIZED AWS CLOUD SERVICES TO PROPEL MEDICAL IMAGING PLATFORM GROWTH 81
TABLE 19 CASE STUDY 2: NHS TRUST ADOPTED INSTANT DATA ACCESS TO ESTABLISH UNIFIED PLATFORM FOR DICOM IMAGE DATA STORAGE AND MANAGEMENT 82
TABLE 20 VNA & PACS MARKET: UNMET NEEDS 83
TABLE 21 VNA & PACS MARKET: END-USER EXPECTATIONS 84
TABLE 22 VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 89
TABLE 23 VNA & PACS MARKET FOR CT, BY COUNTRY, 2023–2030 (USD MILLION) 90
TABLE 24 VNA & PACS MARKET FOR MAMMOGRAPHY, BY COUNTRY,
2023–2030 (USD MILLION) 91
TABLE 25 VNA & PACS MARKET FOR ULTRASOUND, BY COUNTRY,
2023–2030 (USD MILLION) 92
TABLE 26 VNA & PACS MARKET FOR MRI, BY COUNTRY, 2023–2030 (USD MILLION) 93
TABLE 27 VNA & PACS MARKET FOR X-RAY, BY COUNTRY, 2023–2030 (USD MILLION) 95
TABLE 28 VNA & PACS MARKET FOR PET, BY COUNTRY, 2023–2030 (USD MILLION) 96
TABLE 29 VNA & PACS MARKET, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 98
TABLE 30 VNA & PACS MARKET FOR ON-PREMISES DEPLOYMENT MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 99
TABLE 31 VNA & PACS MARKET FOR CLOUD-BASED DEPLOYMENT MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 32 VNA & PACS MARKET FOR HYBRID DEPLOYMENT MODELS, BY COUNTRY,
2023–2030 (USD MILLION) 102
TABLE 33 VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 104
TABLE 34 VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 105
TABLE 35 VNA MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 36 DEPARTMENT VNA MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 37 MULTI-DEPARTMENT VNA MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 38 MULTI-SITE VNA MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 39 PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 109
TABLE 40 PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 41 DEPARTMENT PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 42 MULTI-DEPARTMENT PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 43 MULTI-SITE PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 44 VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 114
TABLE 45 KEY INDEPENDENT VENDORS OPERATING IN MARKET 115
TABLE 46 VNA & PACS MARKET FOR INDEPENDENT VENDORS, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 47 KEY THIRD-PARTY VENDORS OPERATING IN MARKET 116
TABLE 48 VNA & PACS MARKET FOR THIRD-PARTY VENDORS, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 49 VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 119
TABLE 50 VNA & PACS MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 51 VNA & PACS MARKET FOR ORTHOPEDIC, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 52 VNA & PACS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 53 VNA & PACS MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 54 VNA & PACS MARKET FOR OBSTETRICS & GYNECOLOGY, BY COUNTRY,
2023–2030 (USD MILLION) 124
TABLE 55 VNA & PACS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 56 VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 127
TABLE 57 VNA & PACS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 58 VNA & PACS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY,
2023–2030 (USD MILLION) 129
TABLE 59 VNA & PACS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 60 VNA & PACS MARKET FOR OTHER END USERS, BY COUNTRY,
2023–2030 (USD MILLION) 131
TABLE 61 VNA & PACS MARKET, BY REGION, 2023–2030 (USD MILLION) 133
TABLE 62 NORTH AMERICA: VNA & PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 63 NORTH AMERICA: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 135
TABLE 64 NORTH AMERICA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 65 NORTH AMERICA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 66 NORTH AMERICA: VNA & PACS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 136
TABLE 67 NORTH AMERICA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 136
TABLE 68 NORTH AMERICA: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 137
TABLE 69 NORTH AMERICA: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 137
TABLE 70 NORTH AMERICA: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 137
TABLE 71 US: KEY MACROINDICATORS 139
TABLE 72 US: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 139
TABLE 73 US: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 139
TABLE 74 US: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 75 US: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 140
TABLE 76 US: VNA & PACS MARKET, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 140
TABLE 77 US: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 141
TABLE 78 US: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 141
TABLE 79 US: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 141
TABLE 80 CANADA: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 143
TABLE 81 CANADA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 143
TABLE 82 CANADA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 143
TABLE 83 CANADA: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 144
TABLE 84 CANADA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 144
TABLE 85 CANADA: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 144
TABLE 86 CANADA: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 145
TABLE 87 CANADA: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 145
TABLE 88 EUROPE: VNA & PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 89 EUROPE: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 147
TABLE 90 EUROPE: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 91 EUROPE: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 148
TABLE 92 EUROPE: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 148
TABLE 93 EUROPE: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 148
TABLE 94 EUROPE: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 149
TABLE 95 EUROPE: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 149
TABLE 96 EUROPE: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 149
TABLE 97 GERMANY: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 150
TABLE 98 GERMANY: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 151
TABLE 99 GERMANY: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 151
TABLE 100 GERMANY: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 151
TABLE 101 GERMANY: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 152
TABLE 102 GERMANY: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 152
TABLE 103 GERMANY: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 152
TABLE 104 GERMANY: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 153
TABLE 105 UK: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 154
TABLE 106 UK: VNA MARKET, BY TYPE 2023–2030 (USD MILLION) 154
TABLE 107 UK: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 155
TABLE 108 UK: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 155
TABLE 109 UK: VNA & PACS MARKET, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 155
TABLE 110 UK: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 156
TABLE 111 UK: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 156
TABLE 112 UK: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 156
TABLE 113 FRANCE: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 157
TABLE 114 FRANCE: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 157
TABLE 115 FRANCE: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 116 FRANCE: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 158
TABLE 117 FRANCE: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 158
TABLE 118 FRANCE: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 159
TABLE 119 FRANCE: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 159
TABLE 120 FRANCE: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 159
TABLE 121 ITALY: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 160
TABLE 122 ITALY: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 123 ITALY: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 124 ITALY: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 161
TABLE 125 ITALY: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 162
TABLE 126 ITALY: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 162
TABLE 127 ITALY: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 162
TABLE 128 ITALY: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 163
TABLE 129 SPAIN: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 164
TABLE 130 SPAIN: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 131 SPAIN: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 132 SPAIN: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 165
TABLE 133 SPAIN: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 165
TABLE 134 SPAIN: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 165
TABLE 135 SPAIN: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 166
TABLE 136 SPAIN: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 166
TABLE 137 REST OF EUROPE: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 167
TABLE 138 REST OF EUROPE: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 139 REST OF EUROPE: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 140 REST OF EUROPE: VNA & PACS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 168
TABLE 141 REST OF EUROPE: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 168
TABLE 142 REST OF EUROPE: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 168
TABLE 143 REST OF EUROPE: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 169
TABLE 144 REST OF EUROPE: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 169
TABLE 145 ASIA PACIFIC: VNA & PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 146 ASIA PACIFIC: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 171
TABLE 147 ASIA PACIFIC: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 148 ASIA PACIFIC: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 149 ASIA PACIFIC: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 172
TABLE 150 ASIA PACIFIC: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 172
TABLE 151 ASIA PACIFIC: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 173
TABLE 152 ASIA PACIFIC: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 173
TABLE 153 ASIA PACIFIC: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 173
TABLE 154 JAPAN: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 174
TABLE 155 JAPAN: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 156 JAPAN: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 157 JAPAN: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 175
TABLE 158 JAPAN: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 176
TABLE 159 JAPAN: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 176
TABLE 160 JAPAN: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 176
TABLE 161 JAPAN: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 177
TABLE 162 CHINA: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 177
TABLE 163 CHINA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 164 CHINA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 165 CHINA: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 178
TABLE 166 CHINA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 179
TABLE 167 CHINA: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 179
TABLE 168 CHINA: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 179
TABLE 169 CHINA: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 180
TABLE 170 INDIA: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 181
TABLE 171 INDIA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 172 INDIA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 173 INDIA: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 182
TABLE 174 INDIA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 182
TABLE 175 INDIA: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 182
TABLE 176 INDIA: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 183
TABLE 177 INDIA: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 183
TABLE 178 REST OF ASIA PACIFIC: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 184
TABLE 179 REST OF ASIA PACIFIC: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 180 REST OF ASIA PACIFIC: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 181 REST OF ASIA PACIFIC: VNA & PACS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 185
TABLE 182 REST OF ASIA PACIFIC: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 185
TABLE 183 REST OF ASIA PACIFIC: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 185
TABLE 184 REST OF ASIA PACIFIC: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 186
TABLE 185 REST OF ASIA PACIFIC: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 186
TABLE 186 LATIN AMERICA: VNA & PACS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 187 LATIN AMERICA: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 187
TABLE 188 LATIN AMERICA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 187
TABLE 189 LATIN AMERICA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 190 LATIN AMERICA: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 188
TABLE 191 LATIN AMERICA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 188
TABLE 192 LATIN AMERICA: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 189
TABLE 193 LATIN AMERICA: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 189
TABLE 194 LATIN AMERICA: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 189
TABLE 195 BRAZIL: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 190
TABLE 196 BRAZIL: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 197 BRAZIL: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 191
TABLE 198 BRAZIL: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 191
TABLE 199 BRAZIL: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 192
TABLE 200 BRAZIL: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 192
TABLE 201 BRAZIL: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 192
TABLE 202 BRAZIL: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 193
TABLE 203 MEXICO: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 193
TABLE 204 MEXICO: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 205 MEXICO: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 206 MEXICO: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 194
TABLE 207 MEXICO: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 195
TABLE 208 MEXICO: VNA & PACS MARKET, BY VENDOR TYPE, 2023–2030 (USD MILLION) 195
TABLE 209 MEXICO: VNA & PACS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195
TABLE 210 MEXICO: VNA & PACS MARKET, BY END USER, 2023–2030 (USD MILLION) 196
TABLE 211 REST OF LATIN AMERICA: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 196
TABLE 212 REST OF LATIN AMERICA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 213 REST OF LATIN AMERICA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 214 REST OF LATIN AMERICA: VNA & PACS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 197
TABLE 215 REST OF LATIN AMERICA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 198
TABLE 216 REST OF LATIN AMERICA: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 198
TABLE 217 REST OF LATIN AMERICA: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 198
TABLE 218 REST OF LATIN AMERICA: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 199
TABLE 219 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY REGION,
2023–2030 (USD MILLION) 200
TABLE 220 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 200
TABLE 221 MIDDLE EAST & AFRICA: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 222 MIDDLE EAST & AFRICA: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 223 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 201
TABLE 224 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 201
TABLE 225 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 202
TABLE 226 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 202
TABLE 227 MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 203
TABLE 228 GCC COUNTRIES: VNA & PACS MARKET, BY PRODUCT TYPE,
2023–2030 (USD MILLION) 203
TABLE 229 GCC COUNTRIES: VNA MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 230 GCC COUNTRIES: PACS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 231 GCC COUNTRIES: VNA & PACS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 204
TABLE 232 GCC COUNTRIES: VNA & PACS MARKET, BY DEPLOYMENT MODEL,
2023–2030 (USD MILLION) 205
TABLE 233 GCC COUNTRIES: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 205
TABLE 234 GCC COUNTRIES: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 205
TABLE 235 GCC COUNTRIES: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 206
TABLE 236 REST OF MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 206
TABLE 237 REST OF MIDDLE EAST & AFRICA: VNA MARKET, BY TYPE,
2023–2030 (USD MILLION) 207
TABLE 238 REST OF MIDDLE EAST & AFRICA: PACS MARKET, BY TYPE,
2023–2030 (USD MILLION) 207
TABLE 239 REST OF MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 208
TABLE 240 REST OF MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY DEPLOYMENT MODEL, 2023–2030 (USD MILLION) 208
TABLE 241 REST OF MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY VENDOR TYPE,
2023–2030 (USD MILLION) 209
TABLE 242 REST OF MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 209
TABLE 243 REST OF MIDDLE EAST & AFRICA: VNA & PACS MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 244 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN
VNA & PACS MARKET, JANUARY 2022–MAY 2025 211
TABLE 245 VNA & PACS MARKET: DEGREE OF COMPETITION 215
TABLE 246 VNA & PACS MARKET: REGION FOOTPRINT 220
TABLE 247 VNA & PACS MARKET: PRODUCT TYPE FOOTPRINT 221
TABLE 248 VNA & PACS MARKET: DEPLOYMENT MODEL FOOTPRINT 222
TABLE 249 VNA & PACS MARKET: END-USER FOOTPRINT 223
TABLE 250 VNA & PACS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 226
TABLE 251 VNA & PACS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS 227
TABLE 252 VNA & PACS MARKET: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 230
TABLE 253 VNA & PACS MARKET: DEALS, JANUARY 2022–MAY 2025 230
TABLE 254 VNA & PACS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 231
TABLE 255 AGFA-GEVAERT GROUP: COMPANY OVERVIEW 232
TABLE 256 AGFA-GEVAERT GROUP: SOLUTIONS OFFERED 234
TABLE 257 AGFA-GEVAERT GROUP: DEALS, JANUARY 2022–MAY 2025 234
TABLE 258 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 236
TABLE 259 FUJIFILM HOLDINGS CORPORATION: SOLUTIONS OFFERED 237
TABLE 260 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–MAY 2025 239
TABLE 261 FUJIFILM HOLDINGS CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2022–MAY 2025 239
TABLE 262 SECTRA AB: COMPANY OVERVIEW 241
TABLE 263 SECTRA AB: SOLUTIONS OFFERED 242
TABLE 264 GE HEALTHCARE: COMPANY OVERVIEW 244
TABLE 265 GE HEALTHCARE: SOLUTIONS OFFERED 245
TABLE 266 GE HEALTHCARE: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 246
TABLE 267 GE HEALTHCARE: DEALS, JANUARY 2022–MAY 2025 246
TABLE 268 MERATIVE: COMPANY OVERVIEW 248
TABLE 269 MERATIVE: SOLUTIONS OFFERED 248
TABLE 270 MERATIVE: DEALS, JANUARY 2022–MAY 2025 249
TABLE 271 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 250
TABLE 272 KONINKLIJKE PHILIPS N.V.: SOLUTIONS OFFERED 251
TABLE 273 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 252
TABLE 274 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2022–MAY 2025 252
TABLE 275 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 253
TABLE 276 CANON MEDICAL SYSTEMS CORPORATION: SOLUTIONS OFFERED 254
TABLE 277 CANON MEDICAL SYSTEMS CORPORATION: DEALS, JANUARY 2022–MAY 2025 255
TABLE 278 CANON MEDICAL SYSTEMS CORPORATION: EXPANSIONS,
JANUARY 2022–MAY 2025 255
TABLE 279 INTELERAD. INTELERAD.: COMPANY OVERVIEW 256
TABLE 280 INTELERAD. INTELERAD.: SOLUTIONS OFFERED 256
TABLE 281 INTELERAD. INTELERAD.: DEALS, JANUARY 2022–MAY 2025 257
TABLE 282 INTELERAD. INTELERAD.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 257
TABLE 283 PAXERAHEALTH: COMPANY OVERVIEW 258
TABLE 284 PAXERAHEALTH: SOLUTIONS OFFERED 258
TABLE 285 NOVARAD CORPORATION: COMPANY OVERVIEW 259
TABLE 286 NOVARAD CORPORATION: SOLUTIONS OFFERED 259
TABLE 287 HYLAND SOFTWARE, INC.: COMPANY OVERVIEW 260
TABLE 288 HYLAND SOFTWARE, INC.: SOLUTIONS OFFERED 260
TABLE 289 HYLAND SOFTWARE, INC.:DEALS, JANUARY 2022–MAY 2025 261
TABLE 290 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 262
TABLE 291 SIEMENS HEALTHINEERS AG: SOLUTIONS OFFERED 263
TABLE 292 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MAY 2025 264
TABLE 293 BRIDGEHEAD SOFTWARE LTD.: COMPANY OVERVIEW 265
TABLE 294 BRIDGEHEAD SOFTWARE LTD.: SOLUTIONS OFFERED 265
TABLE 295 BRIDGEHEAD SOFTWARE LTD.: DEALS, JANUARY 2022–MAY 2025 266
TABLE 296 CANOPY PARTNERS: COMPANY OVERVIEW 267
TABLE 297 CANOPY PARTNERS: SOLUTIONS OFFERED 267
TABLE 298 CRELIOHEALTH INC.: COMPANY OVERVIEW 268
TABLE 299 CRELIOHEALTH INC.: SOLUTIONS OFFERED 268
TABLE 300 ASPYRA, LLC: COMPANY OVERVIEW 269
TABLE 301 ASPYRA, LLC: SOLUTIONS OFFERED 269
TABLE 302 POSTDICOM: COMPANY OVERVIEW 270
TABLE 303 POSTDICOM: SOLUTIONS OFFERED 270
TABLE 304 MEDICASOFT: COMPANY OVERVIEW 271
TABLE 305 MEDICASOFT: SOLUTIONS OFFERED 271
TABLE 306 ESAOTE S.P.A.: COMPANY OVERVIEW 272
TABLE 307 ESAOTE S.P.A.: SOLUTIONS OFFERED 272
TABLE 308 ESAOTE S.P.A.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 273
TABLE 309 VISUS HEALTH IT GMBH: COMPANY OVERVIEW 274
TABLE 310 VISUS HEALTH IT GMBH: SOLUTIONS OFFERED 274
TABLE 311 ADVAHEALTH SOLUTIONS: COMPANY OVERVIEW 275
TABLE 312 SOFTTEAM SOLUTIONS PVT. LTD.: COMPANY OVERVIEW 276
TABLE 313 ARO SYSTEMS: COMPANY OVERVIEW 276
TABLE 314 CENTRA DATA NETWORKS: COMPANY OVERVIEW 277
TABLE 315 ONEPACS: COMPANY OVERVIEW 277
TABLE 316 DEDALUS S.P.A.: COMPANY OVERVIEW 278
LIST OF FIGURES
FIGURE 1 VNA & PACS MARKET SEGMENTATION & REGIONAL SCOPE 28
FIGURE 2 VNA & PACS MARKET: YEARS CONSIDERED 30
FIGURE 3 VNA & PACS MARKET: RESEARCH DESIGN 32
FIGURE 4 VNA & PACS MARKET: KEY DATA FROM SECONDARY SOURCES 33
FIGURE 5 VNA & PACS MARKET: PRIMARY SOURCES 34
FIGURE 6 VNA & PACS MARKET: KEY DATA FROM PRIMARY SOURCES 35
FIGURE 7 VNA & PACS MARKET: KEY INSIGHTS FROM PRIMARIES 36
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 36
FIGURE 9 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 37
FIGURE 10 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 39
FIGURE 11 VNA & PACS MARKET: BOTTOM-UP APPROACH 40
FIGURE 12 VNA & PACS MARKET: TOP-DOWN APPROACH 40
FIGURE 13 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN VNA & PACS MARKET 43
FIGURE 14 VNA & PACS MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 43
FIGURE 15 VNA & PACS MARKET: DATA TRIANGULATION 45
FIGURE 16 VNA & PACS MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 17 VNA & PACS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION) 49
FIGURE 18 VNA & PACS MARKET, BY DEPLOYMENT MODEL, 2025 VS. 2030 (USD MILLION) 49
FIGURE 19 VNA & PACS MARKET, BY VENDOR TYPE, 2025 VS. 2030 (USD MILLION) 50
FIGURE 20 VNA & PACS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 51
FIGURE 21 VNA & PACS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 51
FIGURE 22 VNA & PACS MARKET: REGIONAL SNAPSHOT 52
FIGURE 23 NEED TO HANDLE GROWING DATA VOLUME TO FUEL DEMAND
FOR VNA AND PACS SOLUTIONS 53
FIGURE 24 JAPAN AND VNA ACCOUNTED FOR SIGNIFICANT MARKET SHARE IN 2024 54
FIGURE 25 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2030 55
FIGURE 26 ASIA PACIFIC TO LEAD MARKET DURING FORECAST PERIOD 56
FIGURE 27 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 56
FIGURE 28 VNA & PACS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
FIGURE 29 VNA & PACS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 64
FIGURE 30 VNA & PACS MARKET: VALUE CHAIN ANALYSIS 65
FIGURE 31 VNA & PACS MARKET: ECOSYSTEM ANALYSIS 67
FIGURE 32 VNA & PACS MARKET: FUNDING AND NUMBER OF DEALS, 2021–2024 69
FIGURE 33 VNA & PACS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MAJOR END USERS 72
FIGURE 35 KEY BUYING CRITERIA FOR MAJOR END USERS 72
FIGURE 36 JURISDICTION AND TOP APPLICANT ANALYSIS IN VNA & PACS MARKET,
JANUARY 2022–MAY 2025 79
FIGURE 37 TOP PATENT APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS)
FOR VNA & PACS SOLUTIONS (JANUARY 2015–MAY 2025) 80
FIGURE 38 NORTH AMERICA: VNA & PACS MARKET SNAPSHOT 134
FIGURE 39 UK: NUMBER OF MEDICAL IMAGING UNDER NATIONAL HEALTH SERVICE (NHS), JANUARY 2022–JANUARY 2023 154
FIGURE 40 ASIA PACIFIC: VNA & PACS MARKET SNAPSHOT 170
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN VNA & PACS MARKET,
2020–2024 (USD MILLION) 213
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VNA & PACS MARKET (2024) 214
FIGURE 43 VNA & PACS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 218
FIGURE 44 VNA & PACS MARKET: COMPANY FOOTPRINT 219
FIGURE 45 VNA & PACS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 225
FIGURE 46 EV/EBITDA OF KEY VENDORS 228
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF VNA AND PACS VENDORS 228
FIGURE 48 VNA & PACS MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS 229
FIGURE 49 AGFA-GEVAERT GROUP: COMPANY SNAPSHOT 233
FIGURE 50 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT 237
FIGURE 51 SECTRA AB: COMPANY SNAPSHOT 242
FIGURE 52 GE HEALTHCARE: COMPANY SNAPSHOT 245
FIGURE 53 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 251
FIGURE 54 CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT 254
FIGURE 55 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 263
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 高圧洗浄機市場 – 2030年までの世界予測 2025-06-12
- 装甲車両市場 – 2030年までの世界予測 2025-06-12
- 工業用ゴム市場 – 2030年までの世界予測 2025-06-12
- 追跡・トレースソリューション市場 – 2030年までの世界予測 2025-06-12
- エクソソーム研究市場 – 2030年までの世界予測 2025-06-10